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OBJECTIVES: No head-to-head clinical trial has compared the efficacy of adali-
mumab versus etanercept as first-line therapy for patients with psoriatic arthritis
(PsA). To bridge this gap, we implemented a matching-adjusted indirect compari-
son of adalimumab versus etanercept for PsA.METHODS: Using methodology de-
veloped by Signorovitch, patient-level data from the adalimumab randomized con-
trolled trial (RCT) ADEPT were reweighted to match baseline characteristics from
the pivotal published etanercept RCT. ADEPT patients were reweighted by their
odds of enrollment in the etanercept trial, estimated using logistic regression
model. Matched characteristics included demographics, baseline clinical mea-
sures, and concomitant treatment. After matching, biologic treatment arms were
compared based on difference from placebo in percent achieving 20%, 50%, or
70% improvement in ACR criteria (ACR20/50/70), percent meeting PsA Response
Criteria (PsARC), mean change in Health Assessment Questionnaire (HAQ), percent
with 50%, 75%, or 90% improvement in PASI (PASI50/75/90), and change from
baseline inmodified total Sharp score (mTSS). Statistical significance was assessed
using weighted Student’s t-tests. RESULTS: After reweighting, baseline character-
istics were exactly matched across trials. Compared with etanercept-treated pa-
tients, adalimumab-treated patients had greater placebo-adjusted rates of ACR70
(23.9% vs. 7.9%), PASI50 (60.5% vs. 29.2%), PASI75 (55.0% vs. 19.5%), and PASI90
(40.2% vs. 2.8%) at Week 24 (all p0.05). Adalimumab-treated patients also had
greater change frombaseline vs. placebo inmTSS (1.77 vs. 0.56, p0.080) atWeek 24
and greater rate of ACR70 (20.6% vs. 9.7%, p0.055) at Week 12. No significant
differences were found for ACR20, ACR50, PsARC, and HAQ change (all p0.1).
CONCLUSIONS: Matching-adjusted indirect comparison of adalimumab vs. etan-
ercept in PsA finds that adalimumab treatment is associated with greater proba-
bility of ACR70, PASI50, PASI75, and PASI90 at Week 24.
PMS38
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OBJECTIVES: The objective of this study is to examine the impact of the doughnut
hole on medication behavior for biologic disease modifying anti-rheumatic drugs
(DMARDs) inMedicare beneficiaries that were diagnosedwith rheumatoid arthritis
(RA).METHODS: A retrospective cohort study was conducted using inpatient, out-
patient and pharmacy claims of a 5% national sample of Medicare beneficiaries
who were diagnosed with RA in 2007. Dual and non-dual eligible beneficiaries who
hit the doughnut hole were identified in order to test for differences in medication
behaviors among these groups. An independent samples t-test was carried out to
test for differences in adherence levels to biologic DMARDs and multiple logistic
regression analyses were carried out to test for differences in switching and dis-
continuation behaviors between the groups. Propensity scores were calculated to
control for demographic factors in the regression analyses. RESULTS: 86% of RA
beneficiaries hit the doughnut hole in 2007, with nearly 66% during the first three
months of the year. Adherence levels of non-dual eligibles were found to be signif-
icantly higher than those for dual-eligibles (p-value  0.001). Non-dual eligibles
were significantly more likely to switch their medication post doughnut hole as
compared to dual eligibles (OR  1.596, CI  1.132–2.249). Also, non-dual eligibles
were more likely to discontinue their medications post hitting the doughnut hole,
although their behavior was not found to be significantly different from the dual
eligibles (OR  1.418, CI  0.935–2.151). CONCLUSIONS:Medicare beneficiaries us-
ing specialty drugs may have to increasingly switch or discontinue their medica-
tions as a result of exceedingly high costs they incur in the doughnut hole. Biologic
DMARDs are required to inhibit progression of RA and thus, beneficiaries suffering
fromRA are not left withmuch of a choice but to incur these high costs if theywant
to successfully manage their disease.
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BACKGROUND: Adherence to osteoporosis medications is suboptimal with re-
ported persistence rates of between 25% and 35% at one year. This results in higher
fracture rates with significant medical costs and hospitalizations. OBJECTIVES: To
critically appraise the literature and determine the most effective adherence-en-
hancing interventions for osteoporosis medications. METHODS: A literature
search usingMedline, EMBASE, Cochrane library and CINAHLwas carried out using
the following keywords: osteoporosis, low bone density, low bonemineral density,
low bone mass, low bone mass density and bisphosphonates, calcium, colecalcif-
erol, estrogens, hormone replacement therapy (HRT), raloxifene, vitamin D and
patient compliance, adherence, concordance, persistence, and interventions, clin-
ical trials, RCT. The search period was January 1st, 1999 to July 31st, 2010. We in-
cluded studies on adult users of osteoporosis medications that tested an adher-
ence-enhancing intervention (e.g. patient education, intensified patient care), and
which reported quantitative results of adherence. Each article was reviewed inde-
pendently by two investigators and disagreements were resolved by consensus.
Downs’ checklist was modified to assess the quality of studies. Due to studies
heterogeneity, the analysis was focused on qualitative assessment. RESULTS: 27
publications were identified including 8 studies which randomized more than
4,500 patients fulfilled the inclusion criteria. Articles on reviews (5), protocols (1),
lack of intervention (7) or no quantitative data on adherence (6) were excluded. The
most frequent intervention was education (6) followed by monitoring/supervision
(2). Four studies used randomization to allocate intervention, which was led by
nurses (3), pharmacists (1), physicians (1) and multidisciplinary teams (2). Fol-
low-up ranged from 3 to 48 months. The average intervention effect size ranged
from 0.12 (education) to 0.24 (patients monitored by nursing staff). The average
quality score was 65.7%. CONCLUSIONS: Themost effective adherence-enhancing
interventions for osteoporosis medications were patient monitoring by nursing
staff and education. Future studies should assess adherence interventions based
on specific pharmacological treatments.
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OBJECTIVES: To determine preferences and marginal willingness to pay (MWTP)
for osteoarthritis (OA) treatments, including complementary and alternative med-
icine (CAM) among a sample of Medicare beneficiaries with mild and moderate-
severe OA.METHODS: A discrete choice conjoint analysis was conducted with 181
participants with OA recruited from 4 senior centers and one internal medicine
practice. Data were analyzed using Sawtooth Software. OA severity was deter-
mined by the brief pain inventory short form (BPI-sf), using previously established
cut points. Utility data and MWTP were derived from multinomial logit analysis.
This study was conducted in accordance with ISPOR’s Checklist for Good Research
Practices in Conjoint Analysis. RESULTS: Prescription pain medication, prayer/
spiritual healing, and over the counter (OTC) medications were the most preferred
treatments for both groups. The utility value for prescription pain medication was
.28 for mild OA and .56 for moderate-severe OA participants. Prayer was the most
preferred CAM treatment with significant utility values of .69 and .78 for mild and
moderate-severe OA participants, respectively. OTC medications had a significant
utility value of .39 for mild OA and .24 for moderate-severe OA participants. Signif-
icant differences were that moderate-severe OA participantshad strong prefer-
ences for acupuncture (.94) and mild OA participants had significant preferences
for massage therapy (.28). The price attribute followed the expected trend as lower
prices were associated with higher utility, although moderate-severe OA partici-
pants were less price sensitive and were willing to pay more for treatment than
mild OA participants. CONCLUSIONS: As OA severity increases, patients become
less price-sensitive. Additionally, OA patients have significant preference for CAM
in addition to conventional treatments. These data suggest that healthcare provid-
ers should involve patients in treatment decisions to optimize treatment accep-
tance and compliance. As options for CAM alone and in conjunction with conven-
tional medications become increasingly available, the relationship between
patient preferences and health outcomes is important to examine.
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BACKGROUND:Gout is themost common inflammatory arthritis inmen above age
40 and its prevalence is rapidly rising. However, the burden of this disease on
health-related quality of life (HRQOL), productivity and healthcare resource utili-
zation from a patient’s perspective has not been well published. OBJECTIVES: To
explore the self-reported gout burden on HRQOL of gout patients (N1468), their
resource utilization, and general health compared to an age/gendermatched gout-
free group controls (N1468). METHODS: Data were obtained from the 2010 US
National Health and Wellness Survey, an annual internet-based survey of nation-
ally representative adults. Respondents reported their health conditions, HRQOL
using SF-12, work and activity impairment (past week), and resource utilization
(past six months). These patients were then compared to an age and gender
matched gout-free cohort using 2-sided t-test or Chi Square test, p 0.05 indicating
statistical significance. RESULTS: The prevalence of self-reported gout in this sur-
veywas 1.9%. 78% of these patientsweremalewith amean age of 60 years, and BMI
of 32.7. 88% were physician diagnosed and 69% were treated with gout-specific
medication. There was no difference in alcohol use between 2 cohorts. The gout
patients however, had significantly higher comorbidity rate for hypertension, hy-
perlipidemia, diabetes, and CHF, 3x rate of Myocardial Infarction, and 4x rate of
moderate/severe renal disease (p 0.05 for all). They had lower SF-12 domain
scores, physical and mental summary scores than gout-free controls (p 0.05).
Fewer gout patientswere employed full time, and larger numberwere on long-term
disability (p 0.05). They had twice the amount of work and social impairment,
double thenumber of ERvisits, hospitalizations, andmeanvisits to varioushealthcare
providers (p 0.05 for all). CONCLUSIONS: Gout patients have significantly lower
HRQOL, larger burden of work and activity impairment, and greater resource utiliza-
tion than gout-free controls.
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OBJECTIVES: In the context of a French national post-marketing study on patients’
satisfaction with routine care management, decision was made to use the Patient
Satisfaction Questionnaire (PSQ III). Developed in the USA, the PSQ-III contains 8
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items related to the financial aspect of caring. The objective was to test the French
translation of the PSQ III and evaluate its content validity considering the local
health care system. METHODS: The French version of the PSQ-III was tested on 5
patients with rheumatoid arthritis. The aim of these cognitive interviews was to
test clarity and comprehension of the translation but also the relevance of the 8
financial items to the French context from the patients’ point of view. RESULTS: A
direct translation of the financial items didn’t prove difficult as they could be ren-
dered literally. Cognitive interviews showed that the items were also easily under-
stood. Respondents mostly didn’t consider the items, however, as relevant to their
situation (e.g. “I worry sometimes about having to pay largemedical bills” or “I have
to pay for more of my medical care that I can afford”) although they showed some
concern regarding future evolution of the reimbursement process in France. After
consultation, the developer of the instrument confirmed that if needed, the items
related to the financial domain could be left aside. Decisionwasmade to create two
versions of the translation: one including the eight financial items and another
excluding them. CONCLUSIONS: As far as health care systems are concerned, lin-
guistic validation goes beyond understanding the text and direct translation of the
relevant items. It requires knowledge of the local context in order to collect mean-
ingful data. The target healthcare system needs to be carefully considered and
adequacy of the translation can be tested through cognitive interviews and con-
sultation with experts in the domain.
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OBJECTIVES: Fibromyalgia is a chronicmusculoskeletal condition characterized by
pain, fatigue, psychological distress, and sleep disturbances. The symptom com-
plexity and existence of comorbid conditions such as anxiety and depression have
been shown to negatively impact patient’s quality of life (QoL). The study objective
is to identify the most commonly used QoL instruments in fibromyalgia and to
examine the instruments’ psychometric properties. METHODS: A systematic
search was conducted from 1990 to 2010 using PUBMED, EBSCOhost, OVID, and
ScienceDirect databases. The search was limited to English language and key
search terms (e.g., fibromyalgia, quality of life) were used to identify articles of
interest. Articles identified were further screened to exclude clinical studies, re-
view papers and studies that discussed development of QoL instruments.
RESULTS: The search yielded 74 articles out of which 40 were included in the final
review. The review identified 11 generic instruments, 6 disease-specific, and 20
condition-specific instruments that were used in fibromyalgia. Short Form 36 was
the most commonly used generic instrument. Among disease-specific instru-
ments, Fibromyalgia Impact Questionnaire (FIQ) was themost commonly used and
has 10 domains (physical functioning, feeling well, work missed, job ability, pain,
fatigue, morning tiredness, stiffness, anxiety, depression). FIQ was found to have
good test-retest reliability (Pearson’s r  0.56-0.95) and construct validity. Beck
Depression Inventory was most commonly used condition-specific instrument.
Most of the reviewed studies assessed pain, fatigue, and sleep disorders using
visual analog scale.CONCLUSIONS: Fibromyalgiahas aprofound impact onpatient’s
quality of life. Among the QoL instruments reviewed, FIQ justifies its use in research
and clinical practice given its varied domains and strong psychometric properties.
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OBJECTIVES: To assess effects of etanercept therapy on vitality using the Health
Assessment Questionnaire (HAQ).METHODS: Eighty-nine patients with moderate
to severe rheumatoid arthritis (RA) were randomized in a phase 2/3 study to eval-
uate efficacy/safety of 25 mg etanercept twice weekly given in combination with
methotrexate. Fifty-nine patients were randomized to etanercept/methotrexate
and 30 to placebo/methotrexate. TheHAQwas administered at baseline, Days 8/15,
and every 4 weeks fromWeeks 424. Vitality was assessed using 4 items: Feel full
of pep? Feel worn out? Have enough energy to do the things you want to do? Feel
tired? Patients responded on a 5-point scale ranging fromAll the time toNever. Using
standard scoring algorithms, the vitality score ranged from 0 (worst) to 100 (best).
Anchor and distribution-basedmethods were employed to estimate theminimally
important difference (MID) for improvement. A repeatedmeasuresmodelwas used
to compare change frombaseline over time between groups. RESULTS:At baseline,
mean vitality scores were 34 with 95% confidence interval (CI) of 30 to 39 for etan-
ercept/methotrexate patients versus 40 (95% CI 33 to 47) for placebo/methotrexate
patients. At Week 24, the unadjusted mean improvements in vitality scores from
baseline were 22 (95% CI 17 to 28) for etanercept/methotrexate versus 8 (95% CI 2 to
15) for placebo/methotrexate patients. The MID was established at 9.0, and 37%
etanercept/methotrexate patients achieved the MID at Day 8 versus 17% placebo/
methotrexate patients. The percentage rose to 67% versus 42% at Week 12, and to
74% versus 38% at Week 24 for etanercept/methotrexate versus placebo/metho-
trexate patients, respectively. The repeated measures model indicated a statisti-
cally significant difference in vitality change from baseline over time between the
treatments (P  0.025). CONCLUSIONS: The vitality MID was achieved by 74% of
patients on etanercept/methotrexate by Week 24 versus 38% on placebo/metho-
trexate.
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OBJECTIVES: To examine willingness-to-pay (WTP) and factors influencing WTP
for treatment to prevent osteoporotic fractures with the stated preference data in
Korean population METHODS: A questionnaire was administered via a trained
interviewer to adult Korean general population. Subjects were selected by a non-
probability sampling via a quota-sampling to reflect the national distribution of
gender and age in Korea. Each respondent answered questions about eight differ-
ent scenarios, each of which specified as different types of fracture (hip and verte-
brae), efficacy of treatment (10% and 50%), and subjects to whom fracture occurred
(self and family). WTP per annumwas elicited with an open question per scenario.
The demographic characteristics of respondents were also collected. A multivari-
ate regression using a generalized linear model with a gamma distribution and
log-link function was performed to identify factors influencing the level of WTP.
RESULTS: Of one hundred and one respondents who completed the survey, the
average of WTP per annum for respondent itself was 550 USD and 1,125 USD for
treatment with 10% and 50% efficacy to reduce vertebral fracture risk, respectively.
Similarly, the average ofWTP per annum for respondent’s family member was 683
USD and 1,333 USD. The annualWTP for respondent itself was 1,017 USD and 1,950
USD for treatment with 10% and 50% efficacy to reduce hip fracture risk, respec-
tively. Education level, income level, the treatment efficacy, age, self-rated health
status, and subjects to whom fracture occurred were significantly associated with
the level of WTP. CONCLUSIONS: Respondents’ preferences for osteoporosis treat-
ment to reduce fracture risk reflected health and non-health related factors. This
research provides useful information to expand the coverage of osteoporosis treat-
ment which reduces the risk of costly fractures. Further research using a double-
bounded, dichotomous-choice type questions utilizing the WTP range based on
this study is ongoing.
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EMPLOYED PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS
Watson C1, Cheng A2, Hone D3, Huang B3, Bitman B1, Huang XY1, Gandra SR1
1Amgen, Inc., Thousand Oaks, CA, USA, 2McKesson Corporation, East Palo Alto, CA, USA,
3McKesson Specialty, Toronto, ON, Canada
OBJECTIVES: To quantify the impact of etanercept (ETN) on work and activity
impairment in employed patients with moderate to severe rheumatoid arthritis
(RA) in US community practices. METHODS: In this prospective, observational
study, 55 sites across the US enrolled employed, TNF-naïve, moderate to severe RA
patients who initiated 50mg/week ETN between January 1, 2009 andMarch 5, 2010.
Telephone interviews were conducted at baseline (prior to or at the time of their
first ETN dose) and 6 months (after the start of ETN), collecting patient demo-
graphic and clinical information, in addition to evaluating work and activity im-
pairment using the Work Productivity and Activity Impairment Questionnaire
(WPAI). The change in WPAI outcomes after 6 months was assessed through a
Wilcoxon signed rank test on all enrolled patients. RESULTS: At baseline, 204 en-
rolled patients (mean age, 46.6 years (SD: 10.9); 72.6% female, 83.8% in full-time
employment; mean duration of RA, 5.2 years) reported that the overall work im-
pairment, work absenteeism, work presenteeism (reduction in productivity at
work) and total activity impairment due to RA were 43.2%, 9.9%, 39.7% and 56.1%,
respectively. All fourWPAI outcomes improved after initiation of ETN therapy. At 6
months, 153 patients remained on therapy and the overall respective WPAI scores
demonstrated a mean percent improvement from baseline of 28.7% (p0.0001),
54.6% (p0.0009), 33.2% (p0.0001) and 37.3% (p0.0001). In addition, mean hours
lost from work over the last 7 days because of RA decreased from 3.8 hours at
baseline to 1.6 hours at 6 months (62.5% decrease in hours lost; p0.0005).
CONCLUSIONS: In working patients with moderate to severe RA, ETN had a signif-
icant impact on reducing overall work impairment, absenteeism, presenteeism,
and activity impairment. Data demonstrate the positive impact of ETN on the
ability to work and perform regular activities when used under real world condi-
tions.
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OBJECTIVES: Estimate/compare employability-adjusted-life-years (EALYs) over time
for rheumatoid arthritis (RA) patients treated with golimumab (GLM)methotrexate
(MTX) vs. placeboMTX in the GO-FORWARD study.METHODS: GO-FORWARD is a
double-blind, placebo-controlled study of adults with active RA (4 tender and 4
swollen joints) and inadequate response to MTX. This analysis included patients
65yrs old who received placeboMTX (MTX) or GLM (50 or 100mg)MTX (GLM)
q4wks. Self-reported employment status and Health Assessment Questionnaire
(HAQ) were assessed through 3 years. A patient was ’unemployable’ if unemployed
and felt unable to work even if a job was available or ’employable’ if employed or
felt well enough to work if a job was available. Long-term (over a 10-yr period)
employability was estimated via logistic regression modeling incorporating age,
gender and HAQ. HAQ was derived using progression rates of 0.045/year for MTX
group and 0 (base case) to 0.025/year (sensitivity analysis) for GLM group. RESULTS:
At baseline, the mean HAQ score was 1.36, and 61.9% and 44.8% of patients 65
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